tetano
Editor, Senior Moderator
J Ophthalmic Inflamm Infect
. 2022 Jan 4;12(1):4.
doi: 10.1186/s12348-021-00275-x.
Ocular inflammatory events following COVID-19 vaccination: a multinational case series
Ilaria Testi[SUP] 1 [/SUP], Camilo Brandão-de-Resende[SUP] 2 [/SUP], Rupesh Agrawal[SUP] 1 3 4 5 6 [/SUP], Carlos Pavesio[SUP] 7 [/SUP], COVID-19 Vaccination Ocular Inflammatory Events Study Group
Collaborators, Affiliations
Abstract
Background: Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine's immunogenicity and safety, especially in patients with pre-existing inflammatory conditions.
Methods: Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021.
Results: Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19-84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1-14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%).
Conclusion: Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.
Keywords: COVID-19; Coronavirus disease; Immunomodulatory; Ocular inflammation; SARS-CoV-2; Uveitis; Vaccination.
. 2022 Jan 4;12(1):4.
doi: 10.1186/s12348-021-00275-x.
Ocular inflammatory events following COVID-19 vaccination: a multinational case series
Ilaria Testi[SUP] 1 [/SUP], Camilo Brandão-de-Resende[SUP] 2 [/SUP], Rupesh Agrawal[SUP] 1 3 4 5 6 [/SUP], Carlos Pavesio[SUP] 7 [/SUP], COVID-19 Vaccination Ocular Inflammatory Events Study Group
Collaborators, Affiliations
- PMID: 34982290
- DOI: 10.1186/s12348-021-00275-x
Abstract
Background: Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine's immunogenicity and safety, especially in patients with pre-existing inflammatory conditions.
Methods: Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021.
Results: Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19-84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1-14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%).
Conclusion: Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.
Keywords: COVID-19; Coronavirus disease; Immunomodulatory; Ocular inflammation; SARS-CoV-2; Uveitis; Vaccination.